P2-196: Combined modality treatment using a non-platinum-containing regimen and concurrent radiotherapy in the treatment of locally-advanced non-small cell lung cancer

Swan Swan Leong, Kam Weng Fong, Wan Teck Lim, Chee Keong Toh, Swee Peng Yap, Eng Huat Tan
2007 Journal of Thoracic Oncology  
In the era of targeted agents, combined chemoradiotherapy remains standard of care for non-resectable stage III non-small cell lung cancer (NSCLC). While recognizing that we have probably reached a plateau in terms of treatment results using this strategy, it is still imperative to reduce toxicities while not compromising efficacy. This study aims to evaluate a non-platinum-containing regimen used in conjunction with radiotherapy. Methods: Patients with histologically proven, non-resectable
more » ... e III NSCLC are eligible for the study. They must be above 18 years old, have good performance status, and have adequate bone marrow, renal and hepatic function. Patients will receive 2 cycles of induction vinorelbine (25mg/m 2 ) and gemcitabine (1000mg/m 2 ) given on days 1 and 8 every 21 days, followed by radiotherapy 60-66Gy with concurrent weekly vinorelbine (15mg/m 2 ). The primary objective is to assess the response rate to this regimen and secondary objectives to assess tolerability and toxicity. Results: We have completed the target accrual of 42 patients. There are 31 males and 11 females. The median age is 65, range of 41 to 79. Sixty-one percent has stage IIIB disease and 38.9% has stage IIIA disease. Forty-four percent of the patients have adenocarcinoma and 25% of patients have squamous cell carcinoma. Fifteen patients (36%) achieved a partial response after induction chemotherapy. After chemoradiotherapy, 7 patients had complete response and 19 patients had partial response, giving an overall response rate of 62%. Toxicity data is available for 36 patients. Nine patients(25%) had grade 3 or 4 neutropenia, 4 patients(11%) had grade 3 esophagitis and 3 patients(8%) had grade 3 fatigue. Conclusion: The toxicities of this regimen are low and the response rate is comparable to similar treatment schedules with platinum-based chemotherapy. Background: concurrent chemoradiotherapy treatment is standard of care for patients with stage III NSCLC and a good performance status.
doi:10.1097/01.jto.0000283854.78557.f8 fatcat:hqkqellmwbb4zlsilzzpgsbawu